Search Results for “cancer” – Page 153 – media

Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.
- Source: Prnewswire
- 764
- January 22, 2018
biopharmaceutical EP4 antagonist Market Views
Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to advance public health measures.
- Source: medicalxpress
- 669
- January 22, 2018
smallpox synthetic DNA synthetic virus vaccine
Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018.
- Source: Prnewswire
- 740
- January 19, 2018
anti-cancer immune New Approvals RM-1929
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL

Novartis today announced that its supplemental Biologics License Application (sBLA) for KymriahTM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for or relapse after autologous stem cell transplant (ASCT) has been accepted by the US Food and Drug Administration (FDA) for Priority Review.
- Source: Novartis
- 400
- January 18, 2018
DLBCL New Approvals sBLA
Pfizer, Foundation Medicine to develop companion diagnostics for oncology treatments

Pfizer has collaborated with Foundation Medicine for the development of companion diagnostics (CDx) for its oncology portfolio.
- Source: invitrodiagnostics.medicaldevices-business-review
- 612
- January 18, 2018
Company Insight oncology Pfizer
NHS Adopts Early Warning Sepsis System

NHS officials have surmised that a system that identifies seriously ill patients would save approximately 2,000 lives a year. They have also estimated that 627,000 ‘bed days’ could be saved as a result.
- Source: Celebrity Angels
- 550
- January 17, 2018
New Approvals NHS sepsis
Teva Announces U.S. FDA Approval of TRISENOX (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved the use of TRISENOX® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The approval was based on a Priority Review by the FDA on data from published scientific literature and a review of Teva’s global safety database for arsenic trioxide
- Source: finance.yahoo
- 545
- January 16, 2018
APL arsenic trioxide FDA New Approvals Teva TRISENOX
Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven

After expanding its partnership with Syndax $SNDX earlier this week on their lead drug, Genentech has beefed up their pipeline of PD-L1 combos with a fresh pact with Stanford spinout Forty Seven.
- Source: Endpts;
- 371
- January 15, 2018
Market Views PD-L1 combos
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 501
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis
GE Healthcare and Roche join forces to create clinical decision support tools

GE Healthcare and Roche have launched a partnership to assist clinicians in making better choices and help patients get individualized care.
- Source: MedCityNews
- 568
- January 12, 2018
Clinical Company Insight Roche

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.